DNA variant linked to weight-loss drug success, study finds
A study using 23andMe Research Institute data of 27,885 people found a GLP1R gene variant was associated with modestly greater weight loss with GLP-1 and GIP-targeting drugs and with higher rates of nausea and vomiting; other health conditions were linked to lower effectiveness.
